Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Target Price at $39.00
by Scott Moore · The Cerbat GemShares of Upstream Bio, Inc. (NASDAQ:UPB – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $39.00.
UPB has been the subject of a number of recent analyst reports. Wall Street Zen cut Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target for the company. in a research note on Friday, March 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st.
Institutional Trading of Upstream Bio
A number of institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new position in shares of Upstream Bio in the 4th quarter valued at approximately $29,000. Torren Management LLC acquired a new position in Upstream Bio during the 4th quarter worth approximately $30,000. BNP Paribas Financial Markets boosted its position in Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after acquiring an additional 2,158 shares during the last quarter. Legal & General Group Plc boosted its position in Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after acquiring an additional 1,440 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in Upstream Bio during the 4th quarter worth approximately $45,000.
Upstream Bio Stock Performance
Shares of NASDAQ:UPB opened at $9.30 on Wednesday. The stock has a market capitalization of $506.11 million, a P/E ratio of -3.48 and a beta of 1.80. Upstream Bio has a 1-year low of $7.25 and a 1-year high of $33.68. The business has a 50-day moving average price of $8.96 and a two-hundred day moving average price of $20.29.
Upstream Bio (NASDAQ:UPB – Get Free Report) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The firm had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.52 million. Upstream Bio had a negative return on equity of 36.48% and a negative net margin of 5,026.03%. As a group, equities analysts predict that Upstream Bio will post -3.02 EPS for the current year.
Upstream Bio Company Profile
Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.
The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.